Seo S, Keam B, Shin SH, Chae YS, et al. A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer. Int J Cancer 2023 Jun 26. doi: 10.1002/ijc.34622.
PMID: 37357950